?Evaluation the effects of Sitagliptin administration in patients with COVID-19

Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200420047147N1

Enrollment

Registered

2020-04-23

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia of COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients in Sitagliptin group receive Sitagliptin (Dr.Abidi Pharmaceuticals, Iran) at dose of 50 mg BID twice a day for totally 10 days and the other standard and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who diagnosed with COVID-19 by RT-PCR test Oxygen saturation less than 93% Age more than 18 years old To sign the informed consent form

Exclusion criteria

Exclusion criteria: Chronic kidney disease Acute kidney injury Chronic liver disease pregnancy or breastfeeding Pancreatitis Allergy to Sitagliptin Pemphigus disease history

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Daily, From admission to discharge time. Method of measurement: Thermometer.;Cough. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Dyspnea. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.	—

Secondary

Measure	Time frame
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Needs to mechanical ventilation. Timepoint: Daily,From admission to discharge time. Method of measurement: Medical Record.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.	—

Measure

Time frame

Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Needs to mechanical ventilation. Timepoint: Daily,From admission to discharge time. Method of measurement: Medical Record.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Dastan

Shahid Beheshti University of Medical Sciences

fzh.dastan@gmail.com+98 21 2610 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026